Real-time disaster intelligence, alerts, and response tools.
Thursday, April 23, 2026
[ad_1] Implements Plan to Accelerate Business Optimization and Achieve Profitability in 2025 Initiates Voluntary Chapter 11 Process to Facilitate Restructuring Initiatives and Ownership Transition Company Secures Interim Financing to Support Operations Customers Will Continue to […]
[ad_1] The study involved end-stage oncology patients with no other suitable treatment options. In this Phase Ib study, Pidnarulex (CX-5461) demonstrated acceptable clinical tolerability and showed preliminary signs of efficacy, even in patients who had […]
[ad_1] HONG KONG, Sept. 8, 2024 /PRNewswire/ — Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in […]
[ad_1] In the ITT population, ivonescimab demonstrated a clinically meaningful mPFS of 11.15 months vs. 5.82 months with pembrolizumab in 1L PD-L1 positive advanced NSCLC. ITT Stratified HR: Ivonescimab significantly reduced the risk of disease […]
[ad_1] PORTLAND, Ore., Sept. 6, 2024 /PRNewswire/ — Eastside Distilling, Inc. (Nasdaq: EAST) (“Eastside” or the “Company”), a consumer-focused beverage company that builds craft inspired experiential brands and high-quality artisan products around premium spirits, digital […]
